{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:12:53Z","timestamp":1783620773004,"version":"3.55.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Measurable residual disease (MRD) analysis, also known as minimal residual disease analysis, has become an essential component of routine clinical management in many hematopoietic neoplasms. Measurable residual disease status in the absence of morphologic disease holds prognostic value and can acutely affect treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Measurable residual disease monitoring is described in acute leukemia, multiple myeloma, and chronic lymphocytic leukemia. We discuss the approach to MRD assessment of these hematologic neoplasms using flow cytometry and molecular techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The appropriate use of available ancillary techniques is crucial to assess patients for MRD. Interpreting these results in the appropriate clinical context is challenging and often requires expertise. Incorporating the results into disease management is critical for improved outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Consensus guidelines on MRD assessment in hematopoietic neoplasms continue to evolve. Further, emerging technologies and laboratory availability are important practical considerations for pathologists who are implementing MRD analysis. From this review, pathologists can gain an anecdotal perspective on the application and interpretation of advanced studies to assess the MRD status of patients with hematopoietic malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag079","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:39Z","timestamp":1783617399000},"source":"Crossref","is-referenced-by-count":0,"title":["The essentials\u2014measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions"],"prefix":"10.1093","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-5826","authenticated-orcid":false,"given":"Savanah D","family":"Gisriel","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Wisconsin\u2013Madison , Madison, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-3653","authenticated-orcid":false,"given":"Alexa","family":"Siddon","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Laboratory Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026070913162987800_aqag079-B1","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/0140-6736(92)92625-p","article-title":"Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia","volume":"340","author":"Lo Coco","year":"1992","journal-title":"Lancet"},{"key":"2026070913162987800_aqag079-B2","doi-asserted-by":"publisher","first-page":"8998","DOI":"10.1073\/pnas.85.23.8998","article-title":"Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer","volume":"85","author":"Frohman","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070913162987800_aqag079-B3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.V80.2.492.bloodjournal802492","article-title":"Molecular monitoring of the myl\/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction","volume":"80","author":"Biondi","year":"1992","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B4","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1073\/pnas.85.15.5698","article-title":"Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro","volume":"85","author":"Kawasaki","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070913162987800_aqag079-B5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1182\/blood.V82.4.1264.1264","article-title":"Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase\/polymerase chain reaction to predict relapse","volume":"82","author":"Huang","year":"1993","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1073\/pnas.87.2.563","article-title":"Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction","volume":"87","author":"Sawyers","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070913162987800_aqag079-B7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0145-2126(81)90002-3","article-title":"Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia","volume":"5","author":"Bradstock","year":"1981","journal-title":"Leuk Res"},{"key":"2026070913162987800_aqag079-B8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/cyto.990060411","article-title":"Detection of minimal disease in acute leukemia using flow cytometry: studies in a rat model for human acute leukemia","volume":"6","author":"Martens","year":"1985","journal-title":"Cytometry"},{"key":"2026070913162987800_aqag079-B9","first-page":"241","article-title":"The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML))","volume":"4","author":"Martens","year":"1990","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/stem.5530080105","article-title":"Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML)","volume":"8","author":"Martens","year":"1990","journal-title":"Int J Cell Cloning"},{"key":"2026070913162987800_aqag079-B11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1046\/j.1365-2141.1998.00675.x","article-title":"Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry","volume":"101","author":"Farahat","year":"1998","journal-title":"Br J Haematol"},{"key":"2026070913162987800_aqag079-B12","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood.v98.6.1746","article-title":"Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification","volume":"98","author":"San Miguel","year":"2001","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B13","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070913162987800_aqag079-B14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/jnci\/88.20.1483","article-title":"Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry","volume":"88","author":"Sievers","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"2026070913162987800_aqag079-B15","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.V90.6.2465","article-title":"Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients","volume":"90","author":"San Miguel","year":"1997","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B16","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood Adv"},{"key":"2026070913162987800_aqag079-B17","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2002-10-3064","article-title":"Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children\u2019s Cancer Group study of 252 patients with acute myeloid leukemia","volume":"101","author":"Sievers","year":"2003","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/ijlh.13070","article-title":"The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation","volume":"41","author":"Wang","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"2026070913162987800_aqag079-B19","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1002\/cpcy.73","article-title":"Acute myeloid leukemia minimal residual disease detection: the difference from normal approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr Protoc Cytom"},{"key":"2026070913162987800_aqag079-B20","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41375-022-01647-5","article-title":"Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia","volume":"36","author":"R\u00f6hnert","year":"2022","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B21","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 Update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B23","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/leu.2016.44","article-title":"Harmonemia: a universal strategy for flow cytometry immunophenotyping\u2014a European LeukemiaNet WP10 study","volume":"30","author":"Lacombe","year":"2016","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B24","first-page":"1726","article-title":"Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia","volume":"9","author":"Steenbergen","year":"1995","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B25","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1038\/sj.leu.2401246","article-title":"Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes","volume":"12","author":"Pongers-Willemse","year":"1998","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B26","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41375-024-02272-0","article-title":"Analysis of measurable residual disease by IG\/TR gene rearrangements: quality assurance and updated EuroMRD guidelines","volume":"38","author":"van der Velden","year":"2024","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sj.leu.2401245","article-title":"Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia","volume":"13","author":"Pongers-Willemse","year":"1999","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/sj.leu.2404535","article-title":"Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B31","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1182\/bloodadvances.2018023432","article-title":"NPM1mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse","volume":"2","author":"H\u00f6llein","year":"2018","journal-title":"Blood Adv"},{"key":"2026070913162987800_aqag079-B32","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/s41467-019-09745-2","article-title":"Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation","volume":"10","author":"Cocciardi","year":"2019","journal-title":"Nat Commun"},{"key":"2026070913162987800_aqag079-B33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood.2023022226","article-title":"MRD in AML: who, what, when, where, and how?","volume":"143","author":"Sahasrabudhe","year":"2024","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026070913162987800_aqag079-B35","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/bloodadvances.2020002846","article-title":"Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS","volume":"4","author":"Huls","year":"2020","journal-title":"Blood Adv"},{"key":"2026070913162987800_aqag079-B36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/biomedicines12030599","article-title":"Measurable residual disease detection in acute myeloid leukemia: current challenges and future directions","volume":"12","author":"Moritz","year":"2024","journal-title":"Biomedicines"},{"key":"2026070913162987800_aqag079-B37","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1182\/bloodadvances.2022009379","article-title":"Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study","volume":"7","author":"Scott","year":"2023","journal-title":"Blood Adv"},{"key":"2026070913162987800_aqag079-B38","doi-asserted-by":"publisher","first-page":"e107587","DOI":"10.1371\/journal.pone.0107587","article-title":"Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia","volume":"9","author":"Terwijn","year":"2014","journal-title":"PLoS One"},{"key":"2026070913162987800_aqag079-B39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38-leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B40","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.16594","article-title":"Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting","volume":"190","author":"Hanekamp","year":"2020","journal-title":"Br J Haematol"},{"key":"2026070913162987800_aqag079-B41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fcell.2020.00249","article-title":"Sequencing-based measurable residual disease testing in acute myeloid leukemia","volume":"8","author":"Yoest","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026070913162987800_aqag079-B42","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/blood-2009-11-253435","article-title":"Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia","volume":"115","author":"Stow","year":"2010","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cyto.b.21939","article-title":"Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion","volume":"100","author":"Tembhare","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"2026070913162987800_aqag079-B45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.6004\/jnccn.2025.0006","article-title":"Pediatric acute lymphoblastic leukemia, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Inaba","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070913162987800_aqag079-B46","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","article-title":"Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts","volume":"9","author":"Short","year":"2025","journal-title":"Blood Adv"},{"key":"2026070913162987800_aqag079-B47","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"key":"2026070913162987800_aqag079-B48","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1182\/bloodadvances.2021006727","article-title":"Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods","volume":"6","author":"Kotrov\u00e1","year":"2022","journal-title":"Blood Adv"},{"key":"2026070913162987800_aqag079-B49","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026070913162987800_aqag079-B50","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B51","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070913162987800_aqag079-B52","doi-asserted-by":"publisher","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070913162987800_aqag079-B53","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B54","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B55","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B56","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B57","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070913162987800_aqag079-B58","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/s41375-018-0132-y","article-title":"Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies","volume":"32","author":"Thompson","year":"2018","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B59","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"key":"2026070913162987800_aqag079-B60","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"key":"2026070913162987800_aqag079-B61","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/hematology.2023000441","article-title":"MRD-directed therapy in CLL: ready for prime time?","volume":"2023","author":"Rhodes","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026070913162987800_aqag079-B62","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/leu.2012.216","article-title":"Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron","year":"2013","journal-title":"Leukemia"},{"key":"2026070913162987800_aqag079-B63","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/cyto.a.24958","article-title":"Development of a 29-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease and leukemic stem cells in acute myeloid leukemia","volume":"107","author":"Zhang","year":"2025","journal-title":"Cytometry A"},{"key":"2026070913162987800_aqag079-B64","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/bloodadvances.2025016126","article-title":"Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry","volume":"10","author":"Seheult","year":"2026","journal-title":"Blood Adv"},{"key":"2026070913162987800_aqag079-B65","doi-asserted-by":"publisher","DOI":"10.64898\/2026.01.22.26343677","article-title":"Whole genome sequencing informed patient personalized measurable residual disease assays for acute myeloid leukemia","author":"Ravindra","year":"2026","journal-title":"Medrxiv"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/1\/aqag079\/68739720\/aqag079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/1\/aqag079\/68739720\/aqag079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:41Z","timestamp":1783617401000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag079\/8729168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag079","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"aqag079"}}